Indications/Uses
As a vasodilator in the treatment of peripheral and vascular disorders.
Dosage/Direction for Use
1 tablet taken 3 times daily with meals. To be taken with some liquid or as prescribed by the physician.
Overdosage
Overdosage with pentoxifylline may be associated with fever, flushing, faintness, hypotension, drowsiness, agitation and seizures.
Administration
Should be taken with food.
Contraindications
Patients with recent retinal or cerebral hemorrhage.
Special Precautions
Patients w/ bleeding risk factors.
Adverse Reactions
Gastrointestinal complaints, cardiac arrhythmias, angina pectoris, flushing. Bleeding events have been reported rarely, usually in association with bleeding risk factors, dizziness and headache.
Drug Interactions
Concomitant administration of warfarin may prolong prothrombin time. Concomitant theophylline and hypertensive therapy may potentiate their action, requiring dosage adjustment.
Storage
Store at a temperature not exceeding 30°C.
Shelf-Life: 24 months.
Shelf-Life: 24 months.
Action
Antiplatelet/Hemorrheologic agent.
Pentoxifylline improves the flow property of blood. It is known to enhance tissue oxygenation. It produces dose-related decrease in blood viscosity. It also inhibits neutrophil adhesion and activation.
Pharmacokinetics: Pentoxifylline is readily absorbed through the gastrointestinal route but undergoes first-pass hepatic metabolism. Some metabolites are active. The apparent plasma t½ of pentoxifylline is reported to be 0.4-0.8 hr; that of the metabolites varies from 1-1.6 hrs. In 24 hrs, most of the dose is excreted in the urine mainly as metabolites and <4½ is recovered as unchanged drug in the feces. Elimination of pentoxifylline is decreased in elderly patients and patients with hepatic disease.
Pentoxifylline improves the flow property of blood. It is known to enhance tissue oxygenation. It produces dose-related decrease in blood viscosity. It also inhibits neutrophil adhesion and activation.
Pharmacokinetics: Pentoxifylline is readily absorbed through the gastrointestinal route but undergoes first-pass hepatic metabolism. Some metabolites are active. The apparent plasma t½ of pentoxifylline is reported to be 0.4-0.8 hr; that of the metabolites varies from 1-1.6 hrs. In 24 hrs, most of the dose is excreted in the urine mainly as metabolites and <4½ is recovered as unchanged drug in the feces. Elimination of pentoxifylline is decreased in elderly patients and patients with hepatic disease.
MedsGo Class
Haemorrheologicals
Features
Brand
Pentox 400
Full Details
Dosage Strength
400 mg
Drug Ingredients
- Pentoxifylline
Drug Packaging
Extended-Release Tablet 1's
Generic Name
Pentoxifylline
Dosage Form
Extended-Release Tablet
Registration Number
DR-XY27090
Drug Classification
Prescription Drug (RX)